




Renew Biotechnologies' Array Replacement

Direct Whole Methlyome Sequencing

Head-To-Head Comparison of Methylation Array vs. dWMS

For decades, methylation arrays have been a staple in epigenetic research due to their accessibility and well-established workflows¹. However, their reliance on predefined loci, bias toward CpG islands, and dependence on bisulfite conversion introduce errors and limit scope^{2,3}. These limitations have driven the need for holistic, unbiased approaches that offer higher sensitivity and deeper insights, particularly in clinical epigenetics⁴

Renew Biotechnologies' (Renew) Direct Whole Methylome Sequencing (dWMS) addresses this need by leveraging Oxford Nanopore Technologies' native long-read sequencing platform. This solution delivers robust genome-wide methylation data with extensive CpG coverage, eliminating the biases of bisulfite-based methods. Enhanced by the user-friendly ModSeqR toolkit, dWMS simplifies analysis and empowers researchers to explore clinical applications with precision and efficiency. Because dWMS uses the ONT platform, nanopore sequencing will be highlighted in this case study.

Challenges in Transitioning to Native Sequencing

Native DNA sequencing platforms, such as Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio), have emerged as strong alternatives to traditional arrays because they sequence DNA in its native states. This capability allows direct detection of epigenetic modifications, including 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), without the chemical damage caused by bisulfite conversion or the synthetic biases of DNA amplification.

Although these platforms were once error-prone⁵, recent advancements in ONT's Kit 14 chemistry, have achieved Q20+ accuracy (>99%)^{6,7} with Q30 accuracy (99.9%) reported using duplex basecalling and super-accurate (SUP) workflows⁸. Despite increasing affordability compared to short-read and array technologies, the complexity of nanopore data analysis remains a barrier to widespread adoption.

This case study demonstrates how Renew's dWMS addresses the challenges of traditional bisulfite-based approaches, offering a robust and flexible solution for genome-wide methylation analysis. To further enhance accessibility and usability, ModSeqR, a proprietary Renew R package, simplifies dWMS analysis workflows. Together, these tools empower researchers to advance epigenetic research and explore clinical applications with greater precision and efficiency.



Direct Whole Methylome Sequencing

Renew's Direct Whole Methylome Sequencing (dWMS) offers a scalable solution to the challenges of traditional approaches, combining a proprietary shearing protocol, optimized library preparation with enhanced ONT chemistry, and direct native whole-genome sequencing on the Nanopore platform. By leveraging native reads and high accuracy, dWMS delivers superior sequencing performance with data-rich outputs for research, biomarker discovery, and clinical development.

dWMS provides extensive, unbiased coverage of over 27 million CpG sites—more than 30 times the coverage offered by traditional arrays (850,000 CpG sites). This bisulfite conversion- and PCR-free approach eliminates common biases, offering a complete and accurate view of the methylation landscape.

Renew's dWMS Service Includes:



Proprietary
Shearing and
Library Prep



ONT Whole
Genome
Sequencing



Accessible
Bioinformatics
Toolkit

Renew's Bioinformatics Toolkit: ModSeqR

The large volume of data generated by dWMS can pose challenges in storage and analysis. Renew Biotechnologies addresses this with two innovative solutions: CH3, a file format that reduces data size by up to 95% (from 20 GB to 1 GB), and ModSeqR, a user-friendly bioinformatics toolkit. The ModSeqR R package allows researchers to extract summary data, perform differential methylation analyses, and visualize results from CH3 files with just a few lines of code, simplifying the transition from arrays to dWMS workflows.

With Renew's dWMS and ModSeqR toolkit, researchers can efficiently access native methylation data without extensive bioinformatics expertise. This integrated solution advances biomarker discovery, population epigenetics, and clinical diagnostics, paving the way for expedited insights into disease mechanisms, the development of predictive biomarkers, and the translation of epigenomic findings into clinical applications.



Methylation Array vs. Renew's dWMS

A Head-to-Head Comparison

Objective

To compare the efficacy of dWMS to traditional methylation array.

Methods

A comparative analysis was conducted to evaluate the performance of traditional methylation arrays and Renew's dWMS across two tissue types (n = 4 per tissue).

To assess traditional array, genomic DNA (gDNA) was extracted from Tissue 1 and Tissue 2, bisulfite converted, hybridized to Infinium HumanMethylation450 BeadChip microarrays (Illumina) and analyzed according to the manufacturer's protocols. To assess Renew's dWMS approach, gDNA was similarly extracted from Tissue 1 and Tissue 2, processed, and sequenced according to the dWMS protocol. Sequencing reads were aligned to the human genome (GRCh38) using the minimap2 software package with the default settings for Nanopore sequencing reads with base modifications identified using the Dorado basecaller.



Expanded CpG Island Coverage

Although the human genome contains approximately 28,890 CpG islands (CGIs) excluding repeat sequences⁹, traditional methylation arrays typically cover only around 26,000 CGIs¹⁰. In our comparative analysis of Tissue 1 and Tissue 2, the EPIC array identified 4,854 differentially methylated CGIs, 92% of which (4,469 CGIs), were also captured by dWMS (Figure 1). dWMS captured an additional 6,166 differentially methylated CGIs, a 2.4-fold increase compared to the array.




Figure 1: In a comparison of two tissue types, dWMS identifies significantly more differentially methylated CpG islands (CGIs) than traditional microarrays. DNA was extracted from Tissue 1 (n = 4) and Tissue 2 (n = 4) and analyzed with both methylation array and dWMS. The dWMS method captured 2.4 times more CGIs with significant differential methylation, including 92% of those detected by the array.

While the potential clinical significance of the 385 differentially methylated CGIs detected by array but not dWMS and the 6,166 CGIs identified by dWMS but not array are uncertain, the approximate 2.4-fold increase in differentially methylated CGI coverage with dWMS highlights its enhanced potential for biomarker discovery and epigenetic research. We suspect that the remaining approximate 8% (385) CGIs not called by the array may be due to biases introduced during DNA treatment and PCR amplification. To further explore this hypothesis, we are currently conducting additional validation studies.



Minimal Batch Effects

Methylation arrays are known to be highly susceptible to batch effects¹¹, which can significantly impact downstream analyses and conclusions¹², potentially leading to systemic false positives¹³.

To assess batch effects, dWMS was performed on the two tissues at two different physical locations with different PromethION machines. The analysis displayed high correlation within each tissue group (Figure 2A, average $r > 0.97$) and clear differentiation between Tissue 1 and Tissue 2, indicating minimal batch effects (Figure 2). These findings support dWMS as a reliable option for scalable epigenetic research and clinical assay development.




Figure 2. Renew's dWMS demonstrates high reproducibility with minimal inter-sample variance within each group. DNA from Tissue 1 (n = 4) and Tissue 2 (n = 4) were sequenced on two different PromethION machines at two different sites. A correlation matrix (A) and principal component analysis (PCA) plot display high similarity within Tissue 1 and Tissue 2 groups (average correlation $r > 0.97$), highlighting minimal variation between the two locations and, therefore, batch effects.



Tissue of Origin

DNA methylation is increasingly investigated in cell-of-origin studies across oncology and other fields to trace the origins of circulating DNA¹⁴. In a comparative analysis of methylation data for tissue-of-origin studies, we evaluated Illumina's EPIC array against Renew's dWMS using the same DNA regions (CpG islands covered by the array). As expected, dWMS captured significantly more CpG sites, enabling a more detailed analysis of cell-type-specific signatures.

In the representative 15 kb region shown in Figure 3, the EPIC array assessed 10 CpG sites, whereas dWMS captured approximately 15 times more. For example, in the 1.5 kb region around position 127,401 kb, the EPIC array identified six CpG sites, showing predominantly methylated sites in Tissue 1 and largely unmethylated sites in Tissue 2. dWMS not only confirmed these findings but also captured a significantly higher number of CpG sites within this region, demonstrating its superior resolution and suitability for complex tissue-of-origin studies.




Figure 3: Superior CpG detection with Renew's dWMS for regional methylation and cell-of-origin analyses. Renew's dWMS significantly outperforms the EPIC array in CpG site detection within a representative 15 kb region. The EPIC array (top two tracks) identifies 10 CpG sites, while dWMS (bottom tracks) detects ~15 times more CpG sites. In the array data, blue bar height represents methylation levels. In the dWMS tracks, each line represents a single read, with red indicating methylated sites and blue indicating unmethylated sites. This expanded coverage highlights dWMS's superior resolution and suitability for complex methylation and tissue-of-origin studies.

The enhanced sequencing quality of dWMS not only matches the data quality and coverage of traditional arrays at array-specific sites but also significantly expands CpG coverage across the genome. With single-molecule resolution, dWMS enables precise analysis of complex methylation patterns that may hold clinical relevance. This capability supports advanced applications such as cell-of-origin studies, disease and aging-specific methylation pattern analyses, early cancer detection through liquid biopsy, and tracking methylation changes in response to environmental factors. By providing comprehensive coverage and single-molecule resolution, Renew's dWMS unlocks new possibilities for exploring the epigenome with unmatched detail.



Efficiency and Usability

Renew's dWMS is both powerful and accessible, designed to optimize data storage, transfer, and analysis. The CH3 file format reduces data size by up to 95%—from 20 GB modkit outputs to just 1 GB. This memory-efficient format stores data in an on-disk database, enabling larger-than-memory tasks. The analysis pipeline is fast and user friendly, performing differential methylation analyses across 27+ million CpGs in approximately 80 seconds on a standard laptop and sliding window calculations (about 3 billion) in roughly 15 minutes.

To support researchers familiar with array workflows, Renew developed the ModSeqR R package, which converts ONT methylation data into array-like formats compatible with tools such as minfi, DMRcate, and chAMP. This solution empowers researchers to efficiently leverage dWMS data within familiar frameworks, facilitating advanced epigenetic insights.

ModSeqR Capabilities


Methylation summaries
by base position

CpG Island coverage

Sliding window analysis

Differential methylation analysis
by region, read, or position

Quality control functions






Figure 4: ModSeqR commands to extract positional, regional, and differential methylation summaries from CH3 files (A) and representative examples of outputs by Positional (B) and Regional (C) Summaries.

Implications and Future Directions

Renew's dWMS significantly outperforms traditional methylation arrays, covering over 27 million CpG sites compared to the ~850,000 typically captured by arrays. This capability allows for the unbiased acquisition of sequence, methylation, and hydroxymethylation data in a single run, delivering more detailed and accurate insights.

With extensive CpG coverage, dWMS enables the discovery of novel epigenetic biomarkers linked to disease and other biological processes. In population epigenetics, it offers a powerful tool for investigating epigenetic variations across cohorts, advancing our understanding of how genetics, lifestyle, and environmental factors shape epigenetic patterns. This precision in capturing the epigenetic landscape opens opportunities for more accurate diagnostics and targeted therapies for improved patient outcomes.



Conclusion

Renew's dWMS represents a transformative advancement in methylation research, leveraging the strengths of nanopore sequencing—rapid throughput, high accuracy, affordability, and portability¹⁵. More than just an alternative, dWMS is a foundational technology poised to redefine epigenomic research and accelerate clinical adoption. Its ability to deliver quality, comprehensive data in a user-friendly format empowers researchers to uncover deeper epigenetic insights and explore the epigenome's critical role in health and disease.

Partnering with Renew Biotechnologies

Unlock The Full Potential Of Your Genomic Research With Renew Biotechnologies.

Learn more at www.renewbt.com

Contact us at info@renewbt.com



Reference List

1. KurdyukovS, Bullock M. DNA methylation analysis: choosing the right method. *Biology*. 2016;5(1):3.
2. Tanaka K, Okamoto A. Degradation of DNA by bisulfite treatment. *Bioorganic & medicinal chemistry letters*. 2007;17(7):1912-1915.
3. Olova N, Krueger F, Andrews S, et al. Comparison of whole-genome bisulfite sequencing library preparation strategies identifies sources of biases affecting DNA methylation data. *Genome biology*. 2018;19(1):1-19.
4. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. *Nature Reviews Genetics*. 2010;11(3):191-203.
5. Marx V. Method of the year: long-read sequencing. *Nature Methods*. 2023/01/01 2023;20(1):6-11. doi:10.1038/s41592-022-01730-W
6. Hofer C, Walchli D, Moncadas LS, Rain-Franco A, Andrei A-S. A high-quality genome of an undescribed *Flavobacterium* species uncovered using Q20+ Nanopore chemistry. *Microbiology Resource Announcements*. 2024;13(1):e00716-23.
7. Sanderson ND, Hopkins KM, Colpus M, et al. Evaluation of the accuracy of bacterial genome reconstruction with Oxford Nanopore R10. 4.1 long-read-only sequencing. *Microbial Genomics*. 2024;10(5):001246.
8. Stock T, Katzenmeier SN, Breiner H-W, Rubel V. Nanopore duplex sequencing as an alternative to Illumina MiSe sequencing for eDNA-based biomonitoring of coastal aquaculture impacts. *Metabarcoding and Metagenomics*. 2024;8:e121817.
9. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001/02/01 2001;409(6822):860-921. doi:10.1038/35057062
10. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. *Genomics*. 2011/10/01/2011;98(4):288-295. doi:https://doi.org/10.1016/j.ygeno.2011.07.007
11. Wilhelm-Benartzi CS, Koestler DC, Karagas MR, et al. Review of processing and analysis methods for DNA methylation array data. *British Journal of Cancer*. 2013/09/01 2013;109(6):1394-1402. doi: 10.1038/bjc.2013.496
12. Sun Z, Chai HS, WuY, et al. Batch effect correction for genome-wide methylation data with Illumina Infinium platform. *BMC Medical Genomics*. 2011/12/16 2011;4(1):84. doi:10.1186/1755-8794-4-84
13. Zindler T, Frieling H, Neyazi A, Bleich S, Friedel E. Simulating ComBat: how batch correction can lead to the systematic introduction of false positive results in DNA methylation microarray studies. *BMC Bioinformatics*. 2020/06/30 2020;21(1):271. doi:10.1186/s12859-020-03559-6
14. Gkoutela S, Castro-Giner F, Szczerba BM, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. *Cell*. 2019;176(1):98-112. e14.
15. Dorey A, Howorka S. Nanopore DNA sequencing technologies and their applications towards single-molecule proteomics. *Nature Chemistry*. 2024/03/01 2024;16(3):314-334. doi:10.1038/s41557-023-01322-x